This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
ILNJ photos One large pine tree shaped cola provided most of the weight with a small popcorn piece tagging along. For more Illinois News Joint reviews, visit here. For more Illinois cannabis industry news, visit here. For Illinois News Joint merchandise and News Joint Printing services, click here.
Food and Drug Administration (FDA), for its Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain. With the move, the company initiated the regulatory process with the FDA. Innocan Pharma Corporation INNO IP INNPF announced on Monday that it has submitted its letter of application for a Pre-IND meeting with the U.S.
IXHL, a cannabinoid and psychedelic medicine biotechnology company, announced the successful completion of a pre-investigational new drug meeting with the U.S. Food and Drug Administration (FDA) regarding the development of CannQuit-O for the treatment of opioid use disorder (OUD). A number of FDA representatives shared insights on.
First and foremost the biggest news in emergency regs on delivery was there is actually a new delivery license. Cause that’s how it works with everything else that the FDA controls. So I’m going to focus mostly on non-storefront retailers or delivery services in this segment. See if this is working.
After multiphase clinical trials were completed, an FDA panel recommended approval of a CBD-based pharmaceutical called Epidiolex for treatment of certain specific and rare types of juvenile epilepsy. The good news is that a reputable company will gladly provide this information. These statements have not been evaluated by the FDA.
The FDA’s proposal responds to a lawsuit from the African American Tobacco Control Leadership Council calling for the national ban, which would target makers and sellers, not users, of menthols and flavored cigars. Tobacco companies will likely challenge the decision in court, according to Stat News. FDA confronts a health inequity.
Even for CBD products which are typically not subject to regulatory licenses (yet at least), the FDA still has authority over certain imports ( see response to Q15 ), so transhippers are may wind up getting doubly tagged by the FDA. If you do not realize the U.S. government (and even the U.S.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content